Servier embarks on another collaboration in immuno-oncology – The Pharma Letter (registration)
The Pharma Letter (registration) |
Servier embarks on another collaboration in immuno-oncology
The Pharma Letter (registration) France’s Servier Laboratories and Transgene have started working together to try to develop simpler, faster and more effective ways of engineering CAR-T cell … Servier and Transgene Have Become Partners to Apply Viral Vectorization Technology to the Engineering of Allogenic …PharmiWeb.com (press release) |
Weekly Register |
Abeona Therapeutics Receives FDA Orphan Drug Designation for ABO-201 Juvenile Batten Disease Gene Therapy …
Nasdaq NEW YORK and CLEVELAND, June 29, 2017 (GLOBE NEWSWIRE) — Abeona Therapeutics Inc. (Nasdaq:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel gene therapies for life-threatening rare diseases, announced … Is Abeona Therapeutics Incorporated (NASDAQ:ABEO)’s Fuel Running Low? Reports Show More SellersWeekly Register |
Nature.com |
Macrophages steal the show
Nature.com The past decade has seen remarkable advances in tumour immunology due to extensive research on inhibition of programmed cell death protein 1 (PD1) — which is expressed on T cells — and its ligand PDL1, which is expressed on tumour cells. However … |